PEMF for
Endometriosis Pain.

July 2026 · 10 min read · Women's Health Protocol

Endometriosis in the Philippines: A Large, Underserved Market

Endometriosis — the growth of endometrial-like tissue outside the uterus — affects approximately 10–15% of women of reproductive age worldwide. In the Philippines, with a female population of approximately 55 million, this translates to an estimated 2.7–4.1 million women with endometriosis, the majority of whom remain undiagnosed or inadequately treated.

The diagnostic delay in the Philippines is significant: women report an average of 6–10 years between symptom onset and formal diagnosis. During this period, the primary management is either no treatment, NSAID-dependent pain control, or empirical hormonal suppression (combined oral contraceptives, progestins, GnRH agonists). Each of these approaches carries limitations that create a gap in the market for non-pharmacological, non-hormonal adjunct pain management — a gap that PEMF is well-positioned to fill.

The Pain Pathophysiology: Why PEMF Is Mechanistically Relevant

Endometriosis pain arises from three overlapping, PEMF-addressable mechanisms:

1. Prostaglandin-driven inflammation: Ectopic endometrial tissue produces prostaglandins (PGE2, PGF2α) in high concentrations, driving local pelvic inflammation, uterine hypercontractility, and sensitization of pelvic nociceptors. PEMF suppresses cyclooxygenase-2 (COX-2) activity and NF-κB transcription, reducing prostaglandin synthesis at the source — the same mechanism that makes NSAIDs effective, but without the gastrointestinal side effects or the ceiling of analgesic effect.
2. Peripheral sensitization: Chronic pelvic inflammation in endometriosis sensitizes the pelvic visceral afferent network — lower-threshold A-δ and C fibers generate pain at stimuli that would normally be non-painful. PEMF's membrane stabilization effect raises nociceptor firing thresholds, reducing the peripheral sensitization component of chronic pelvic pain (evidence: PMC11914662, n=91, 36% pain reduction vs. 10%, p<0.0001).
3. Central sensitization: In patients with long-standing endometriosis, central pain processing becomes dysregulated — the same mechanism seen in fibromyalgia and other central sensitization syndromes. PEMF has documented effects on adenosine-A2A receptor activation in the dorsal horn and cortisol normalization (PMC9748435: cortisol -28%), which modulate the central sensitization component.

Additionally, PEMF's anti-fibrotic effects via TGF-β modulation may reduce adhesion formation over long-term treatment — though this is a mechanistic hypothesis not yet confirmed in dedicated endometriosis RCTs.

The Key Evidence: Pelvic Pain RCTs

The three most clinically relevant RCTs specifically address PEMF for cyclical and chronic pelvic pain — the primary pain phenotype of endometriosis:

Roozbeh et al. (n=55, published Iranian Journal of Reproductive Medicine)

Double-blind RCT: 5 Hz, 10 mT PEMF vs. sham over 3 menstrual cycles. Active group: VAS 7.4 → 3.2 (vs. 7.1 → 6.1 in sham, p<0.001). NSAID consumption reduced by 68% in the PEMF group vs. 8% in sham. Both dysmenorrhea and non-menstrual pelvic pain improved. No adverse events.

Gharloghi et al. (n=60)

RCT using 60 Hz PEMF for 3 cycles: pain intensity reduced 56% in PEMF group vs. 12% in sham. Pain duration per cycle: 18.4 → 7.2 hours in PEMF group vs. minimal change in sham. Quality of life measures improved significantly in the PEMF group.

Dolatian et al. (n=42)

Three-month follow-up RCT: 60 Hz PEMF. VAS 7.1 → 2.3 at 3-month assessment — representing a 68% reduction from baseline. Effect sustained throughout the follow-up period, suggesting durable biological rather than purely symptomatic action.

Collectively, these three independent RCTs demonstrate consistent, large-effect PEMF benefit on pelvic pain — the primary symptom domain of endometriosis. The evidence is directly applicable because the prostaglandin-driven pelvic inflammation in dysmenorrhea (the studied condition) and endometriosis shares the same molecular pathway.

Evidence Summary Table

Clinical Protocol for Endometriosis Pain Management

PEMF vs. Current Endometriosis Pain Management Options

The Hormonal Suppression Gap: Where PEMF Fits

Current evidence-based management guidelines recommend hormonal suppression (OCP, progestins, GnRH agonists) as first-line medical treatment for endometriosis pain. However, a significant subset of patients are poor candidates for or decline hormonal therapy:

• Women seeking pregnancy: GnRH agonists and OCP are contraceptive — not suitable for women actively trying to conceive
• Women with hormone-sensitive conditions: prior thromboembolic events, migraine with aura, estrogen-receptor-positive history
• Patients experiencing intolerable side effects: mood disruption, libido loss, and weight changes cause 20–40% discontinuation rates with hormonal therapy
• Adolescents and young women: who prefer to avoid hormonal therapy for personal or cultural reasons — a particularly relevant population in the Philippines
• Perimenopausal women with endometriosis: hormonal manipulation is more complex; non-pharmacological options are preferred

For all these segments, PEMF offers a clinically effective, non-hormonal, non-surgical pain management option with no systemic side effects, no fertility impact, and no bone density compromise. This represents a well-defined, unmet clinical need.

The Philippine Women's Health Clinic Opportunity

Endometriosis management in the Philippines remains largely confined to OB-GYN clinics and tertiary hospital outpatient departments. Standalone women's wellness clinics, integrative medicine centers, and physiotherapy practices with a women's health specialization represent an underserved segment where PEMF can differentiate the service offering.

A clinic offering PEMF as an adjunct to standard gynecological care can target: (1) endometriosis patients seeking non-hormonal pain management; (2) dysmenorrhea patients (a far larger population, 45–90% of reproductive-age women experience some form of painful menstruation); and (3) post-laparoscopic excision patients requiring chronic maintenance — a high-retention, recurring revenue model.

At 70+ Israeli clinics (population: 9M) already offering pelvic pain applications — now expanding to the Philippines — the protocols and outcomes data are well-established.

Contraindications

PEMF is contraindicated in: active cardiac pacemaker, active pregnancy (first trimester; monitoring required thereafter), active epilepsy, and active malignancy in the treatment area. There is no contraindication for IUD use (Mirena, Copper T) — the magnetic field does not interact with intrauterine devices. Ovarian endometrioma ("chocolate cyst") does not contraindicate PEMF; the field is not sufficient to rupture or alter cyst integrity. The treatment coil is placed externally over the lower abdomen and sacrum — no internal placement is involved.

Frequently Asked Questions

Can PEMF be used while trying to conceive?

Yes. PEMF has no contraceptive effect and no documented impact on fertility, implantation, or early embryogenesis at clinical field intensities. Unlike GnRH agonists and OCP — which suppress ovulation — PEMF provides pain management without any cycle interference. Women undergoing IVF or IUI can receive PEMF treatment without modification to their fertility protocol; clinical review with their reproductive endocrinologist is recommended as standard of care.

How long before results are noticeable?

The RCT data (Roozbeh, Gharloghi, Dolatian) showed measurable pain reduction over 2–3 menstrual cycles — roughly 6–12 weeks of treatment. In clinical practice, many patients report reduced cycle pain from the first month of treatment. The 3-month VAS data (7.1 → 2.3, Dolatian) represents the stabilized endpoint — suggesting ongoing improvement with continued treatment. Unlike NSAIDs, which act acutely but have no disease-modifying effect, PEMF's anti-inflammatory mechanism may produce durable improvement that extends beyond active treatment.

Is PEMF compatible with laparoscopic excision or ablation?

Yes, PEMF is fully compatible as an adjunct before and after laparoscopic surgery. Pre-operatively, PEMF can reduce pelvic inflammation, potentially improving surgical visualization. Post-operatively, PEMF accelerates wound healing and peritoneal recovery (same mechanism as post-surgical RCT evidence: PMID 28060214). Long-term post-excision PEMF maintenance addresses the chronic inflammatory component that drives the 40–50% five-year recurrence rate — the key clinical challenge in surgical endometriosis management.